These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 6428959

  • 1. Induction of transplantation resistance to murine L1210 leukemia cells in BCG-primed mice by immunization with tuberculin protein-coupled L1210 cells.
    Ohno R, Kodera Y, Ogura M, Yamada H.
    Gan; 1984 Feb; 75(2):187-92. PubMed ID: 6428959
    [Abstract] [Full Text] [Related]

  • 2. Effect of OK-432 on immunization with mitomycin-C-treated L1210 cells.
    Ryoyama K, Murayama T, Koshimura S.
    Gan; 1979 Feb; 70(1):75-82. PubMed ID: 376388
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapy with neuraminidase-treated cells and bacillus Calmette-Guerin.
    Kollmorgen GM, Killion JJ, Sansing WA, Cantrell JL, Bundren JC, LeFever AV.
    Surgery; 1976 Feb; 79(02):202-8. PubMed ID: 1108258
    [Abstract] [Full Text] [Related]

  • 4. Mitomycin C-augmented production of I-A antigen-positive macrophages in tumor vaccine-primed mice.
    Kataoka T, Yamamoto T, Honjo K, Murayama T.
    Jpn J Cancer Res; 1986 Mar; 77(3):305-11. PubMed ID: 3009373
    [Abstract] [Full Text] [Related]

  • 5. Properties of interferon induced by purified protein derivative of tuberculin in mice sensitized with BCG or cell-wall skeleton of BCG.
    Takeyama H, Kawashima K, Yamada K, Ito Y.
    Gan; 1979 Aug; 70(4):421-8. PubMed ID: 389726
    [Abstract] [Full Text] [Related]

  • 6. High-grade tumor-specific immunity induced by L1210 leukemia variants obtained from the culture of L1210 cells fused with Lesch-Nyhan fibroblasts.
    Kawashima K, Nagura E, Watanabe E, Mizoguchi K, Saga S, Isobe K, Nakashima I, Yamada K, Oikawa T, Kojima K.
    Int J Cancer; 1983 Oct 15; 32(4):507-14. PubMed ID: 6618710
    [Abstract] [Full Text] [Related]

  • 7. Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A.
    Kataoka T, Oh-hashi F, Tsukagoshi S, Sakurai Y.
    Cancer Res; 1977 Apr 15; 37(4):964-8. PubMed ID: 403001
    [Abstract] [Full Text] [Related]

  • 8. Synergy between low-dose chemotherapy and immunotherapy in mouse L1210 leukemia.
    Relyveld EH, Bizzini B, Ophir R, Ben-Efraim S.
    Cancer Treat Rep; 1987 Mar 15; 71(3):241-6. PubMed ID: 3102055
    [Abstract] [Full Text] [Related]

  • 9. Induction of tumor resistance in mice by L1210 leukemia cells persistently infected with HVJ (Sendai virus).
    Takeyama H, Kawashima K, Yamada K, Ito Y.
    Gan; 1979 Aug 15; 70(4):493-501. PubMed ID: 229053
    [Abstract] [Full Text] [Related]

  • 10. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
    Ujiie T.
    Jpn J Cancer Res; 1987 Jul 15; 78(7):737-47. PubMed ID: 3114200
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy.
    Mathé G, Halle-Pannenko O, Bourut C.
    Natl Cancer Inst Monogr; 1973 Dec 15; 39():107-13. PubMed ID: 4150738
    [No Abstract] [Full Text] [Related]

  • 14. Endogenous production of TNF in mice long after BCG sensitization.
    Satoh M, Inagawa H, Minagawa H, Kajikawa T, Oshima H, Abe S, Yamazaki M, Mizuno D.
    J Biol Response Mod; 1986 Apr 15; 5(2):117-23. PubMed ID: 3525760
    [Abstract] [Full Text] [Related]

  • 15. Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells.
    Takatsu K, Hamaoka T, Tominaga A, Kanamasa Y.
    J Immunol; 1980 Dec 15; 125(6):2367-73. PubMed ID: 6776192
    [Abstract] [Full Text] [Related]

  • 16. Correlations between humoral immunity and successful chemotherapy-immunotherapy.
    Cantrell JL, Killion JJ, Kollmorgen GM.
    Cancer Res; 1976 Sep 15; 36(9 pt.1):3051-7. PubMed ID: 788896
    [Abstract] [Full Text] [Related]

  • 17. The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice.
    Vyakarnam A, Lachmann PJ, Sikora K.
    Immunology; 1981 Feb 15; 42(2):337-48. PubMed ID: 6161889
    [Abstract] [Full Text] [Related]

  • 18. Immunotherapeutic response of concanavalin A-bound L1210 vaccine enhanced by a streptococcal immunopotentiator, OK-432.
    Kataoka T, Oh-hashi F, Sakurai Y.
    Cancer Res; 1979 Jul 15; 39(7 Pt 1):2807-10. PubMed ID: 445486
    [Abstract] [Full Text] [Related]

  • 19. Successful immunotherapy with micrococcus, BCG or related polysaccharides on L1210 leukaemia after BCNU chemotherapy.
    Verloes R, Atassi G, Dumont P, Kanarek L.
    Br J Cancer; 1981 Feb 15; 43(2):201-9. PubMed ID: 7470382
    [Abstract] [Full Text] [Related]

  • 20. Active immunotherapy in spontaneous leukemia of AkR mice.
    Mathé G, Halle-Pannenko O, Bourut C.
    Exp Hematol; 1973 Feb 15; 1(2):110-4. PubMed ID: 4609352
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.